Brii Biosciences
3
15M
3
0.60
1
- Areas of investment
Summary
In 2018 was created Brii Biosciences, which is appeared as Corporate Investor. The main office of represented Corporate Investor is situated in the San Francisco. The venture was found in North America in United States.
The current fund was established by Zhi Hong.
Among the various public portfolio startups of the fund, we may underline Artizan Biosciences For fund there is a match between the location of its establishment and the land of its numerous investments - United States. We can highlight the next thriving fund investment areas, such as Life Science, Biotechnology. Moreover, a startup needs to be at the age of 2-3 years to get the investment from the fund.
The usual things for fund are deals in the range of 10 - 50 millions dollars. The fund is constantly included in 2-6 deals per year. The top activity for fund was in 2019.
The standard case for the fund is to invest in rounds with 5 partakers. Despite the Brii Biosciences, startups are often financed by Malin Corporation, Hatteras Venture Partners. The meaningful sponsors for the fund in investment in the same round are OUP (Osage University Partners), Mountain Group Capital, Marin Investments.
Investments analytics
Analytics
- Total investments
- 3
- Lead investments
- 0
- Exits
- 1
- Rounds per year
- 0.60
- Investments by industry
- Biotechnology (3)
- Health Care (2)
- Life Science (1)
- Biopharma (1)
- Pharmaceutical (1) Show 1 more
- Investments by region
-
- United States (3)
- Peak activity year
- 2019
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 11
- Group Appearance index
- 0.67
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| AN2 Therapeutics | 21 Nov 2019 | Biotechnology, Health Care, Pharmaceutical | Early Stage Venture | 12M | United States, California |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.